1. A bacterial strain selected from the group consisting of L. paracasei LMG P-21380, L. plantarum LMG P-21021, Bifidobacterium lactis LMG P-21384 and Bifidobacterium breve DSM 16604 or their cellular components, as an inducer of interleukin-10.2. The bacterial strain of claim 1, wherein said bacterium exhibits an IL-10 / IL-12 ratio of more than 1 and less than 150, preferably of 10 to 100, more preferably of 30 to 60.3. The bacterial strain Bifidobacterium breve DSM 16604 according to claim 1 as an inducer of interleukin-10 and showing an IL-10 / IL-12 ratio of 50 to 100, preferably 70 to 80.4. A bacterial strain according to any one of claims 1 to 3, wherein said bacterium is in the form of a living bacterium or a killed bacterium or its cellular components. A food product containing at least one bacterial strain according to any one of claims 1 to 4 as an active ingredient. A composition comprising at least one bacterial strain according to any one of claims 1 to 4 for use as a medicine. The composition according to claim 6 for use as a medicine for the prevention or treatment of inflammatory conditions of the large intestine and small intestine. The composition of claim 7, wherein the inflammatory conditions are selected from the group comprising Crohn's disease and ulcerative colitis. The composition of claim 6 for use as a medicament for the prevention or treatment of functional bowel disorders. The composition of claim 9, wherein the functional bowel disorders are selected from the group consisting of diarrhea and constipation. The use of at least one bacterial strain according to any one of claims 1 to 4 for the manufacture of a medicinal product for p1. Бактериальный штамм, выбранный из группы, состоящей из L. paracasei LMG P-21380, L. plantarum LMG P-21021, Bifidobacterium lactis LMG Р-21384 и Bifidobacterium breve DSM 16604 или их клеточных компонентов, в качестве индуктора интерлейкина-10.2. Бактериальный штамм по п.1, где указанная бактерия демонстриру
